The multiplication of analogs, the best strategy for rapid extension of the Oncostatic Arsenal G. MathéC. Jasmin Editorial Pages: 203 - 205
Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin M. HayatC. BourutG. Mathé Original Articles Pages: 217 - 221
Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-α-tocopheryl acetate or coenzyme Q10 in mouse (doxorubicin, toxicity, lipid peroxide, tocopherol, coenzyme Q10) Naoki YamanakaTaketoshi KatoKazuo Ota Original Articles Pages: 223 - 227
2′-Deoxycytidine hydrochloride protection of mice against the lethal toxicity of cytosine arabinoside V. M. BuchmanN. I. BelyanchikovaG. J. Svet-Moldavsky Original Articles Pages: 229 - 234
Enhancement of methotrexate absorption by subdivision of dose W. H. SteeleJ. F. B. StuartJ. G. McVie Original Articles Pages: 235 - 237
Bioavailability of methotrexate: Implications for clinical use J. F. B. StuartK. C. ClamanJ. G. McVie Original Articles Pages: 239 - 241
Human pharmacolinetics of the daunorubicin-DNA complex R. HulhovenG. SokalC. Harvengt Original Articles Pages: 243 - 247
Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals F. VillaniG. BerettaA. Guindani Original Articles Pages: 249 - 251
The disposition of cyclophosphamide in a group of myeloma patients Vivien BramwellR. T. CalvertD. Crowther Original Articles Pages: 253 - 259
Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors Franca FormelliAnna Maria CasazzaCarmen Pollini Original Articles Pages: 261 - 269